We are live on ! Find out more
AVDL

Avadel Pharmaceuticals

Delisted

AVDL was delisted on the 11th of February, 2026.

56 hedge funds and large institutions have $211M invested in Avadel Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

717% more call options, than puts

Call options by funds: $29.6M | Put options by funds: $3.62M

300% more funds holding in top 10

Funds holding in top 10: 14 (+3)

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

52% more capital invested

Capital invested by funds: $139M → $211M (+$72.5M)

33% more funds holding

Funds holding: 4256 (+14)

22.5% more ownership

Funds ownership: 49.08%71.59% (+23%)

53% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 15

Holders
56
Holders Change
+14
Holders Change %
+33.33%
% of All Funds
1.23%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.09%
New
25
Increased
7
Reduced
15
Closed
8
Calls
$29.6M
Puts
$3.62M
Net Calls
+$26M
Net Calls Change
+$23.8M

AVDL Hedge Fund Activity: Q1 2020 in Review

56 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2020, worth a combined $211M — up 52% from $139M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new AVDL positions and 8 closed out — a net gain of 17 holders — while 7 added to existing stakes and 15 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $33.5M. The largest seller was Brandes Investment Partners, cutting an estimated $15.5M.

  • 56 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2020, up from 42 in Q4 2019.
  • Funds reported $211M of Avadel Pharmaceuticals stock for Q1 2020, up 52% quarter-over-quarter.
  • 25 funds opened new Avadel Pharmaceuticals positions in Q1 2020 and 8 closed out, a net change of +17 holders.
  • The largest Avadel Pharmaceuticals buyer in Q1 2020 was Avoro Capital Advisors, an estimated $33.5M added.
  • The largest Avadel Pharmaceuticals seller in Q1 2020 was Brandes Investment Partners, an estimated $15.5M sold.

Based on aggregated 13F filings for Q1 2020.